与多发性一过性白点综合征相关的脉络膜新生血管接受玻璃体内雷珠单抗治疗。
Choroidal Neovascularization Associated with Multiple Evanescent White Dot Syndrome Treated with Intravitreal Ranibizumab.
机构信息
a Department of Ophthalmology , University Vita-Salute, San Raffaele Hospital , Milan , Italy.
b Fondazione G. B. Bietti per l'Oftalmologia, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico) , Rome , Italy.
出版信息
Ocul Immunol Inflamm. 2018;26(4):608-611. doi: 10.1080/09273948.2016.1247175. Epub 2016 Nov 28.
PURPOSE
To describe the clinical outcomes of intravitreal ranibizumab treatment for subfoveal choroidal neovascularization (CNV) associated with multiple evanescent white dot syndrome (MEWDS).
METHODS
This is a prospective, interventional, case series. All recruited patients underwent a baseline intravitreal ranibizumab injection and were monitored monthly over a 12-month follow-up, following a pro-re-nata regimen.
RESULTS
Four patients (four eyes) were included in the study. Mean best-corrected visual acuity (BCVA) changed from 0.60 ± 0.20 at baseline to 0.07 ± 0.05 logMAR at 12-month examination. Baseline central macular thickness reduced from 330 ± 32 µm to the final value of 228 ± 14 µm at the 1-year follow-up. Overall, a mean number of 2.2 ranibizumab injections were administered at the end of 12 months.
CONCLUSIONS
Intravitreal ranibizumab treatment represents a valuable therapeutic option for the management of CNV associated with MEWDS.
目的
描述与多发性一过性白点综合征（MEWDS）相关的脉络膜新生血管（CNV）患者接受玻璃体内雷珠单抗治疗的临床结果。
方法
这是一项前瞻性、干预性、病例系列研究。所有入组患者均接受基线玻璃体内雷珠单抗注射，并在 12 个月的随访期间根据 pro-re-nata 方案每月进行监测。
结果
本研究纳入了 4 名患者（4 只眼）。最佳矫正视力（BCVA）从基线时的 0.60 ± 0.20 变化至 12 个月检查时的 0.07 ± 0.05 logMAR。基线中央黄斑厚度从 330 ± 32 µm 减少至 1 年随访时的最终值 228 ± 14 µm。总体而言，在 12 个月结束时平均注射了 2.2 次雷珠单抗。
结论
玻璃体内雷珠单抗治疗是治疗与 MEWDS 相关的 CNV 的一种有价值的治疗选择。
Zotero 插件